Key Points
- Benjamin Looker, Esperion's General Counsel, sold 6,517 shares at an average price of $3.67 for a total of $23,917.39, trimming his stake by 1.66% to 385,905 shares; the sale was disclosed in an SEC filing.
- Esperion reported Q3 EPS of -$0.16 (missing estimates) but revenue of $87.31M beat expectations, and the stock was trading around $3.80 (12‑month range $0.69–$4.13).
- Analysts lean positive with an average rating of "Moderate Buy" and an average price target of $7.20, while institutional investors own about 47.39% of the company (Vanguard holds ~12.09M shares).
Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) General Counsel Benjamin Looker sold 6,517 shares of Esperion Therapeutics stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total value of $23,917.39. Following the completion of the transaction, the general counsel owned 385,905 shares in the company, valued at approximately $1,416,271.35. The trade was a 1.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Esperion Therapeutics Stock Up 4.1%
Shares of ESPR stock opened at $3.80 on Friday. The business has a fifty day simple moving average of $3.19 and a 200 day simple moving average of $2.29. The company has a market cap of $908.43 million, a P/E ratio of -7.60 and a beta of 1.01. Esperion Therapeutics, Inc. has a twelve month low of $0.69 and a twelve month high of $4.13.
Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.07). The business had revenue of $87.31 million during the quarter, compared to analysts' expectations of $78.33 million. As a group, equities research analysts anticipate that Esperion Therapeutics, Inc. will post -0.29 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in shares of Esperion Therapeutics by 3.2% in the 3rd quarter. Vanguard Group Inc. now owns 12,092,449 shares of the biopharmaceutical company's stock valued at $32,045,000 after buying an additional 375,620 shares during the last quarter. Two Seas Capital LP raised its position in shares of Esperion Therapeutics by 43.6% during the second quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company's stock worth $9,800,000 after acquiring an additional 3,024,104 shares during the last quarter. Marshall Wace LLP raised its position in shares of Esperion Therapeutics by 46.2% during the second quarter. Marshall Wace LLP now owns 5,312,252 shares of the biopharmaceutical company's stock worth $5,206,000 after acquiring an additional 1,679,294 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Esperion Therapeutics by 3.1% in the second quarter. Geode Capital Management LLC now owns 4,583,988 shares of the biopharmaceutical company's stock worth $4,513,000 after acquiring an additional 137,691 shares during the period. Finally, Nuveen LLC bought a new stake in Esperion Therapeutics in the first quarter valued at approximately $4,446,000. 47.39% of the stock is owned by institutional investors.
Analysts Set New Price Targets
ESPR has been the subject of several research reports. Piper Sandler assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, November 25th. They issued an "overweight" rating and a $9.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, September 19th. Weiss Ratings restated a "sell (d-)" rating on shares of Esperion Therapeutics in a research report on Wednesday, October 8th. Citigroup reaffirmed a "market outperform" rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Esperion Therapeutics has an average rating of "Moderate Buy" and an average price target of $7.20.
Read Our Latest Report on Esperion Therapeutics
About Esperion Therapeutics
(
Get Free Report)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
